These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32321326)

  • 1. Barriers and facilitators of exploiting the potential of value-added medicines.
    Petykó ZI; Inotai A; Holtorf AP; Brixner D; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):229-236. PubMed ID: 32321326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.
    Kaló Z; Petykó ZI; Fricke FU; Maniadakis N; Tesař T; Podrazilová K; Espin J; Inotai A
    Cost Eff Resour Alloc; 2021 Jul; 19(1):42. PubMed ID: 34266465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings.
    Petykó ZI; Kaló Z; Espin J; Podrazilová K; Tesař T; Maniadakis N; Fricke FU; Inotai A
    Cost Eff Resour Alloc; 2021 Aug; 19(1):57. PubMed ID: 34465350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 8. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Societal value of generic medicines beyond cost-saving through reduced prices.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):701-11. PubMed ID: 25695926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.